<DOC>
	<DOC>NCT00143247</DOC>
	<brief_summary>This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).</brief_summary>
	<brief_title>Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study was terminated on Oct. 18, 2007. This study is not a post approval commitment study. Pfizer decided to cancel new trials because of the decision to withdraw Exubera® (inhaled insulin) due to lack of market performance and not for safety reasons.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects with Type 1 or Type 2 Diabetes Mellitus who participated in previous Phase 2 extension protocols Smoking Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>